KR102771170B1 - 가교-결합제 및 관련 방법 - Google Patents

가교-결합제 및 관련 방법 Download PDF

Info

Publication number
KR102771170B1
KR102771170B1 KR1020187028639A KR20187028639A KR102771170B1 KR 102771170 B1 KR102771170 B1 KR 102771170B1 KR 1020187028639 A KR1020187028639 A KR 1020187028639A KR 20187028639 A KR20187028639 A KR 20187028639A KR 102771170 B1 KR102771170 B1 KR 102771170B1
Authority
KR
South Korea
Prior art keywords
copper
composition
containing material
cross
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028639A
Other languages
English (en)
Korean (ko)
Other versions
KR20180119654A (ko
Inventor
발라무랄리 케이. 암바티
히로노리 우에하라
산토쉬 무다나
Original Assignee
유니버시티 오브 유타 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리서치 파운데이션 filed Critical 유니버시티 오브 유타 리서치 파운데이션
Priority to KR1020257005160A priority Critical patent/KR20250026890A/ko
Publication of KR20180119654A publication Critical patent/KR20180119654A/ko
Application granted granted Critical
Publication of KR102771170B1 publication Critical patent/KR102771170B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187028639A 2016-03-08 2016-12-06 가교-결합제 및 관련 방법 Active KR102771170B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257005160A KR20250026890A (ko) 2016-03-08 2016-12-06 가교-결합제 및 관련 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305227P 2016-03-08 2016-03-08
US62/305,227 2016-03-08
PCT/US2016/065215 WO2017155580A1 (en) 2016-03-08 2016-12-06 Cross-linking agents and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257005160A Division KR20250026890A (ko) 2016-03-08 2016-12-06 가교-결합제 및 관련 방법

Publications (2)

Publication Number Publication Date
KR20180119654A KR20180119654A (ko) 2018-11-02
KR102771170B1 true KR102771170B1 (ko) 2025-02-24

Family

ID=59790799

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187028639A Active KR102771170B1 (ko) 2016-03-08 2016-12-06 가교-결합제 및 관련 방법
KR1020257005160A Pending KR20250026890A (ko) 2016-03-08 2016-12-06 가교-결합제 및 관련 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257005160A Pending KR20250026890A (ko) 2016-03-08 2016-12-06 가교-결합제 및 관련 방법

Country Status (8)

Country Link
US (3) US11065275B2 (https=)
EP (2) EP3426262B1 (https=)
JP (3) JP6929010B2 (https=)
KR (2) KR102771170B1 (https=)
AU (2) AU2016396661B2 (https=)
CA (1) CA3016688A1 (https=)
ES (1) ES2959242T3 (https=)
WO (1) WO2017155580A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
WO2013149075A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
EP3426262B1 (en) * 2016-03-08 2023-08-23 University of Utah Research Foundation Cross-linking agents and associated methods
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
CA3127824A1 (en) 2019-01-25 2020-07-30 Avedro, Inc. Bis(diazirine) derivatives as photo-crossslinker for treating corneal ectatic disorders
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN114082960B (zh) * 2021-11-11 2023-01-17 江苏徐工工程机械研究院有限公司 轴套的制备方法、轴套及挖掘机
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490389A (en) * 1976-03-11 1984-12-25 Nelson Research & Development Co. Contact lens preserving solution containing ascorbic acid or salts thereof
JPH05503527A (ja) * 1990-02-22 1993-06-10 マクノート・ピーティーワイ・リミテッド 人工涙液
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5997911A (en) * 1996-08-27 1999-12-07 Brinton Veterinary Supply, Inc. Composition and method for reducing diarrhea in poultry and swine
JPH10273322A (ja) * 1997-01-30 1998-10-13 Kubota Corp 抗菌性複合チタン酸化合物およびその製造方法
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
CA2431651A1 (en) * 2000-11-16 2002-05-23 Kenneth T. Zeiler Antifungal nail composition and method of use
WO2006020231A2 (en) 2004-07-21 2006-02-23 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060165611A1 (en) 2005-01-26 2006-07-27 National Research Laboratories, Ltd. Composition for Treating and Preventing Periodontal Disease and Method of Use
US20060276777A1 (en) 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
AU2007330356B2 (en) * 2006-12-07 2013-05-02 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
WO2008124009A2 (en) * 2007-04-02 2008-10-16 The Cleveland Clinic Foundation Treating glaucoma
JP2013506005A (ja) 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． 眼の繊維症の処置のための方法及び組成物
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
BRPI1002523B1 (pt) * 2010-07-14 2020-06-02 Universidade Federal De Minas Gerais Processo de síntese de complexos de cobre com atividade antitumoral
WO2014065863A1 (en) * 2012-10-22 2014-05-01 The Regents Of The University Of California Compositions and methods for promoting collagen-crosslinking
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
DE102014012675A1 (de) * 2014-08-26 2016-03-03 Wavelight Gmbh Vernetzung von Augengewebe
BR112017021374A2 (pt) * 2015-04-09 2018-07-03 Laboratori Baldacci S.P.A. ácido pirrolidona carboxílico (pca) para uso oftálmico
EP3426262B1 (en) * 2016-03-08 2023-08-23 University of Utah Research Foundation Cross-linking agents and associated methods
AU2019205774B2 (en) * 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology

Also Published As

Publication number Publication date
JP2021185154A (ja) 2021-12-09
EP3426262A1 (en) 2019-01-16
EP3426262A4 (en) 2019-10-16
US20210322470A1 (en) 2021-10-21
EP3426262C0 (en) 2023-08-23
US20260041714A1 (en) 2026-02-12
AU2023202236A1 (en) 2023-05-04
AU2023202236B2 (en) 2025-05-29
KR20250026890A (ko) 2025-02-25
JP2023153926A (ja) 2023-10-18
CA3016688A1 (en) 2017-09-14
ES2959242T3 (es) 2024-02-22
KR20180119654A (ko) 2018-11-02
WO2017155580A1 (en) 2017-09-14
AU2016396661B2 (en) 2023-01-19
JP6929010B2 (ja) 2021-09-01
JP2019511493A (ja) 2019-04-25
EP4324454A3 (en) 2024-05-01
AU2016396661A1 (en) 2018-09-27
EP4324454A2 (en) 2024-02-21
US11065275B2 (en) 2021-07-20
US20190083529A1 (en) 2019-03-21
EP3426262B1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
KR102771170B1 (ko) 가교-결합제 및 관련 방법
US20240398705A1 (en) Ophthalmic composition
US12544400B2 (en) Treatment of myopic progression
Pfeiffer et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components
Hui et al. In vivo studies evaluating the use of contact lenses for drug delivery
US20240122974A1 (en) Treatment of myopia
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211203

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240626

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241115

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250218

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration